Emergent CFO retires mid-turnaround; treasurer steps in, no permanent pick yet

Emergent makes vaccines and treatments for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose. It reports two segments: Commercial Products, led by NARCAN nasal spray, and medical countermeasures, the drugs governments stockpile against attacks and outbreaks.¹ The American government is the largest buyer of those countermeasures, and it mostly buys under long-term fixed-price contracts with yearly options.² Revenue fell 29% to $742.9 million in 2025, and naloxone sales fell 43% to $226.1 million. Emergent names Teva, Padagis and Amneal as generic rivals, and in September it told investors the overall naloxone market is trending lower than it expected.³

2026 has been rough on reported profit. Second-quarter revenue jumped to $234.3 million, helped by the timing of government smallpox vaccine orders, but a $191.3 million non-cash write-down of the NARCAN business produced a $180.2 million net loss for the quarter.¹ On August 5, 2026, Emergent cut its 2026 forecast: revenue to $645 to $675 million from $720 to $760 million, an $80 million cut at the midpoint, and adjusted EBITDA to $130 to $150 million from $155 to $175 million.² The same day it announced a restructuring that cuts about 93 jobs and is expected to save about $40.0 million a year once fully in place.³

The stock fell 29.58% to close at $5.31 on August 6, 2026, according to a law firm's notice. Several plaintiffs' firms, including Pomerantz and Levi & Korsinsky, then said they were investigating whether Emergent or its officers broke securities laws.¹ Levi & Korsinsky's notice points to Lindahl's earlier remark that softer NARCAN demand came from the long government shutdown and near-term market uncertainty. Emergent's own quarterly report, filed August 6, 2026, four days before the first law-firm notice, said there were no material developments in the legal proceedings it had already disclosed.²

Much of the past year's work was on the balance sheet. In April 2026 Emergent replaced its old term loan with a $150.0 million loan due 2031 from lenders led by OrbiMed, priced at a benchmark short-term rate (with a 3.00% floor) plus 6.25%.¹ On Sept. 03, 2026 it said it had bought back $75 million of its 3.875% bonds due 2028 for about $68 million in cash, an average of 90.6% of face value, leaving about $364.7 million outstanding. It also won a $24 million order for more CYFENDUS anthrax vaccine doses.²

Lindahl came to Emergent in 2018 after serving as CFO of CEB, a public company. Vargo joined in December 2019 as a director of corporate financial planning, after finance jobs at Under Armour and in the aerospace and defense industry, and was named treasurer in November 2025.

Lindahl stops being the principal financial and accounting officer on December 31, 2026, and stays as an advisor until he retires on March 31, 2027. His advisor pay will be materially consistent with his current pay, and his job includes helping prepare and file the annual report for 2026.¹ Vargo becomes interim CFO and principal accounting officer on January 1, 2027. His base salary is $328,000, and the board added $3,850 per pay period while he serves. His salary, bonus and equity awards otherwise stay at the level of his old job.²

Emergent did not disclose Lindahl's current pay, so only Vargo's side of the exchange has a stated price. Emergent keeps paying Lindahl about what he earns now for three more months and pays Vargo a stipend; in return it keeps its longtime finance chief on hand through the year-end close and puts its own treasurer in the top finance job.¹ The company calls the change part of its multi-year transformation plan.²

The filings put no dollar cost on the change beyond Vargo's stipend. To size the company instead: at the October 14 close of $6.91, Emergent's 51,273,336 shares were worth about $354.3 million.¹ At $6.265 at 10:47 a.m. on October 16, down 9.3% from that October 14 close (our price file has no October 15 close), the shares were worth about $321.2 million. In our price file, which starts in mid-September, the stock had closed between $6.33 and $7.24 before this news.² Adding June 30 net debt adjusted only for the September bond buyback, about $443 million, gives a total value near $764 million, or about 5.9 times the low end of 2026 adjusted EBITDA guidance; that net debt ignores the $145 million of receivables collected in July, so the true figure is likely lower.³

Reported and adjusted results tell different stories. In the second quarter, the net loss was $180.2 million, but adjusted EBITDA was $96.5 million, because $276.7 million of items were added back. The biggest was the $191.3 million non-cash NARCAN write-down, and a $20.5 million loss on refinancing debt was another.¹ Emergent's adjusted EBITDA starts from net income and adds back depreciation, amortization, taxes, interest, impairments and other items, and since early 2026 it also leaves out stock pay. In the year to June 30, 2026, adding back only interest, taxes, depreciation and amortization still leaves a loss of about $5.3 million, against adjusted EBITDA of $241.0 million.²

Cash tells a third story. Operating cash flow in the first half of 2026 was $22.3 million and equipment purchases were $4.5 million, leaving about $17.8 million of free cash flow, yet cash still fell $65.7 million after a $50.4 million Ebanga milestone payment and $18.0 million of share buybacks. It was held down by a $107.7 million rise in money owed by customers; receivables stood at $190.0 million at June 30, up from $84.2 million at the end of 2025.¹ The company said $145 million of its $190 million of receivables had been collected by the end of July.²

Cash was $139.7 million at June 30, 2026, and Emergent has another $50 million it can borrow on its revolving credit line, a standing loan it can draw as needed. The September bond buyback used about $68 million of cash, but $145 million of the $190 million of June receivables had already been collected by the end of July, so September 30 cash is unknown until November 2; June cash less the buyback alone, $71.7 million, would understate it.¹ A $75.0 million delayed-draw loan exists, but only if secured debt stays at or below 1.75 times EBITDA as the loan defines it, and it was undrawn at June 30. Emergent says its cash, borrowing and operating cash flow are enough for at least the next twelve months.²

The real deadline is the bonds. The remaining $364.7 million is due August 15, 2028, and if more than $75.0 million is still outstanding 91 days before then, the term loan comes due early unless a liquidity test in the loan is met. The revolving line moves its own due date up to May 17, 2028 if any of the bonds remain, so all $364.7 million bears on it.¹ So about $289.7 million of bonds would need to be repaid or refinanced unless the liquidity test is met, and the company says it is weighing when to refinance. Replacement debt could cost more: the term loan charges at least 9.25% a year, against 3.875% on the bonds.²

On the company's measure, net debt of $450.0 million was 1.9 times trailing adjusted EBITDA of $241.0 million. Spending about $68 million to retire $75 million of bonds cut net debt by about $7 million, to roughly $443 million on June 30 cash, before the $145 million collected in July. Against the low end of 2026 adjusted EBITDA guidance, $130 million, that is about 3.4 times.¹ The term loan caps total leverage at 5.25 times, tested each quarter starting with the one ending September 30, 2026, and Emergent was in compliance at June 30. Gross debt after the buyback, $515 million, is about 4.0 times that low-end figure, inside the cap; the loan uses its own EBITDA definition, so this is only a rough check.²

Interest coverage is thinner than the leverage figure suggests. Emergent assumes about $40 million of interest expense in 2026, so the low end of its EBITDA guidance covers that about 3.3 times. In the year to June 30, 2026, adjusted EBITDA covered $46.4 million of net interest about 5.2 times.

The forecast is the bear's best point. Emergent's full-year 2026 adjusted EBITDA range is $130 to $150 million. It earned $132.0 million in the first half of 2026, so the range implies a second half between a loss of about $2 million and a gain of about $18 million.¹ Third-quarter revenue guidance is $110 to $130 million, against $234.3 million in the second quarter. The company expects its quarterly results to keep varying.²

Emergent had 51,273,336 shares outstanding on July 30, 2026. Warrants for 2.5 million more shares, at $9.88 to $15.72, run to August 2029 and sit well above today's price, and 6.9 million potential shares were left out of second-quarter per-share math as anti-dilutive.¹ There is $37.5 million left on a share buyback that runs through March 31, 2027. The company warns that raising money by selling stock would dilute holders.² Lenders come first: the term loan has a first lien on its priority collateral and the revolving line on its own, both ahead of the unsecured bonds, and shareholders stand last. American Century funds reported 5.4% of the stock at June 30, 2026 as passive holders.³

Insider selling around the news has been small. Director Donald DeGolyer sold 17,800 shares at $7.09 on October 7 under a trading plan adopted in August 2025. Products chief Paul Williams sold 3,000 shares at $6.53 earlier in October.

The bull case: the handoff is orderly and debt is falling. Gross debt was $515 million after the September buyback, against $700 million a year earlier, and the bonds were bought back below face value.¹ The first half produced $132.0 million of adjusted EBITDA, most of the June receivables were collected by July, and Emergent may receive up to $30.0 million of earn-out payments from Bavarian Nordic tied to 2026 sales of two vaccines it sold. Restructuring savings of about $40.0 million a year are still to come.²

The bear case, strongest first. One: the forecast implies almost no adjusted EBITDA in the second half, while all $364.7 million of bonds mature in August 2028 and the revolving line comes due in May 2028 if any remain.¹ Two: the finance chief who stood behind guidance that was later cut is leaving, and the replacement is only interim.² Three: NARCAN faces generics that are sometimes given away, aggressive pricing is eroding prices across the sector, and Emergent warns of possible further write-downs. Four: the American government is the largest buyer of countermeasures, so its order timing drives results.³

Emergent's own forward case is a set of goals, not results: 2026 revenue of $645 to $675 million, with countermeasure sales flat to slightly down and commercial sales down 20% to 25%, and adjusted EBITDA of $130 to $150 million.¹ It also expects about $40.0 million of yearly restructuring savings and plans to refinance the remaining bonds at a time it judges best.²

Dates to watch: third-quarter results on November 2, 2026, which cover the first leverage test; Lindahl's last day as CFO on December 31, 2026; and Vargo's start on January 1, 2027.¹ Then comes the 2026 annual report, which Lindahl is to help file; last year's was filed February 26, 2026. On March 31, 2027 Lindahl retires and the share buyback authority ends.²

What would prove the calm reading wrong: third-quarter revenue below the $110 million low end, another cut to the $130 to $150 million EBITDA range on November 2, or no refinancing plan for the bonds before the annual report. A named permanent CFO and a bond refinancing would support the bull case.

Emergent named Vargo only as interim CFO and gave no timeline or process for choosing a permanent one.

The filing says he steps down as CFO and later retires, and gives no other reason. Whether the timing has anything to do with the August forecast cut or the law-firm inquiries is not known.

The filing says his advisor pay will be materially consistent with his current pay, but it gives no dollar figure and names no separation payment.

The filing gives the raise per pay period but does not say how many pay periods he has a year.

Emergent has not yet reported its cash or its leverage ratio for the quarter that ended September 30, 2026, the first one tested against the 5.25-times cap. Both should come with results on November 2, 2026.

The company says it is weighing the timing of a refinancing but has named no lender, size or interest rate.